NON-VANGUARD FUNDS

FXH First Trust Health Care AlphaDEX® Fund

Category

Health

Asset class

Specialty

NAV price

$103.84

as of 03/14/2025

Overview

Key facts

Asset class

Specialty

Category

Health

Inception date

05/08/2007

Fund Number

N328

Price

NAV Price

$103.84

as of 03/14/2025

NAV Change

increased$1.34 (1.31%)

as of 03/14/2025

Product summary
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the StrataQuant® Health Care Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is a modified equal-dollar weighted index to objectively identify and select stocks from the Russell 1000® Index in the health care sector that may generate positive alpha relative to traditional passive-style indices through the use of the AlphaDEX® selection methodology.
Fund management

Manager Tenure: 15 years

Performance & fees

Total returns
Month-end/Quarterly Pre-Tax Toggle

as of 02/28/2025

Recent returns

Average annual

Month-end3-Month totalYTD1-yr3-yr5-yr10-yr

Since inception

05/08/2007

FXH (Market price)-3.66%-3.95%2.60%0.55%-1.05%6.34%5.26%9.96%
FXH (NAV)
-3.68%-4.01%2.43%0.54%-1.06%6.33%5.26%9.96%

Benchmark

as of 12/31/2024

Year

Total return by NAV

20241.10%
2023-4.50%
2022-12.21%
202115.18%
202027.85%
201922.31%
2018-1.26%
201721.78%
2016-5.20%
20150.23%
Gross Expense Ratio

This information is temporarily unavailable.

Historical volatility measures

This information is temporararily unavailable

The performance data shown represent past performance, which is not a guarantee of future results. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data cited. The performance of an index is not an exact representation of any particular investment, as you cannot invest directly in an index.

Price

Current market price

Current price as of Mon Mar 17 14:53:13GMT+0 2025

Market price change

increased$0.66 (0.64%)

Open

$103.41

High

$104.50

Low

$103.41

Bid/Ask spread

$0.21 (0.20%)

Volume

4,582

Size

10 X 13

Tick

UP

Quotes delayed at least 15 minutes. Source: FactSet.

Historical prices
Chart/Table Toggle
NameDateNAV
FXH 02/28/2025
$106.81

This chart can’t be displayed on mobile devices. For the best viewing experience, visit this page from your desktop or laptop.

Portfolio composition

Characteristics

as of 02/27/2025

FundamentalFXH
Number of stocks
Median market cap
Earnings growth rate
Short-term reserves 0.2%
P/E ratio
P/B ratio
Turnover rate (Fiscal Year-end 07/31/2024) 98.0%
Return on equity
Foreign holdings 1.9%
Fund total net assets as of
Stylebox

Equity

Market Captialization Mid Investment Style Blend

Weighted exposures

as of 02/27/2025

99.25%Healthcare
SectorsFXHHealthcare99.25%Industrials0.75%

Weighted equity exposures exclude any temporary cash investments and equity index futures. Some short-term fixed income securities are classified as cash and are excluded from the weighted bond exposures.

Month end 10 largest holdings

24.43% of total net assets as of 02/27/2025

RankHoldings% of fund
1Royalty Pharma PLC Class A2.83%
2Doximity Inc Class A2.82%
3Intra-Cellular Therapies Inc2.66%
4Jazz Pharmaceuticals PLC2.52%
5Exelixis Inc2.45%
6Cardinal Health Inc2.33%
7Tenet Healthcare Corp2.24%
8Universal Health Services Inc Class B2.24%
9Acadia Healthcare Co Inc2.20%
10Natera Inc2.14%

Performance & fees

1

Most recent data available. © 2023 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; (3) does not constitute investment advice offered by Morningstar; and (4) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

© 2023 Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

Target-date investments are subject to the risks of their underlying funds. The year in the investment name refers to the approximate year (the target date) when an investor would retire and leave the workforce. The investment will gradually shift its emphasis from more aggressive investments to more conservative ones based on its target date. A target-date investment is not guaranteed at any time, including on or after the target date.

Bond funds are subject to the risk that an issuer will fail to make payments on time, and that bond prices will decline because of rising interest rates or negative perceptions of an issuer's ability to make payments.

U.S. government backing of Treasury or agency securities applies only to the underlying securities and does not prevent share-price fluctuations. Unlike stocks and bonds, U.S. Treasury bills are guaranteed as to the timely payment of principal and interest.

Although the income from a municipal bond fund is exempt from federal tax, you may owe taxes on any capital gains realized through the fund's trading or through your own redemption of shares. For some investors, a portion of the fund's income may be subject to state and local taxes, as well as to the federal Alternative Minimum Tax.

High-yield bonds generally have medium- and lower-range credit quality ratings and are therefore subject to a higher level of credit risk than bonds with higher credit quality ratings.

Derivatives are subject to a number of risks, such as liquidity risk interest rate risk, market risk, credit risk, and management risk.  A fund investing in a derivative instrument could lose more than the principal amount invested.

Prices of mid- and small-cap stocks often fluctuate more than those of large-company stocks.

Stocks of companies based in emerging markets are subject to national and regional political and economic risks and to the risk of currency fluctuations. These risks are especially high in emerging markets.

Currency hedging risk is the chance that currency hedging transactions may not perfectly offset a fund's foreign currency exposures and may eliminate any chance for a fund to benefit from favorable fluctuations in relevant currency exchange rates. Funds incur expenses to hedge currency exposures.

ESG funds are subject to ESG investment risk, which is the chance that the stocks or bonds screened by the index provider or advisor, as applicable, for ESG criteria generally will underperform the market as a whole or, in the aggregate, will trail returns of other funds screened for ESG criteria. The index provider or advisor’s assessment of a company, based on the company’s level of involvement in a particular industry or their own ESG criteria, may differ from that of other funds or an investor’s assessment of such company. As a result, the companies deemed eligible by the index provider or advisor may not reflect the beliefs and values of any particular investor and may not exhibit positive or favorable ESG characteristics. The evaluation of companies for ESG screening or integration is dependent on the timely and accurate reporting of ESG data by the companies. Successful application of the screens will depend on the index provider or advisor's proper identification and analysis of ESG data. The advisor may not be successful in assessing and identifying companies that have or will have a positive impact or support a given position. In some circumstances, companies could ultimately have a negative impact or no impact or support a given position.

Fund price provided by Refinitiv. Disclaimer. Additional data on this page provided by Morningstar®. Disclaimer.

Fund prices are provided or calculated using data from third-party sources. Vanguard is not responsible for the accuracy or timeliness of third-party data.